US · 1 sources covering this

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

Hindustan TimesLean L·2h ago
Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease
The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults
Read at Hindustan Times →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/daf81e84872da6cc73d1bcdcbe808603255fe13e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease"></iframe>

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

How 1 sources are covering this

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

More from US

RRR echoes at New York City Hall as Zohran Mamdani presents Rental Rip-off report

Drawing flak over power curbs, Kerala State Electricity Board seeks nod for procuring 200 MW for one-year period

Supreme Court to hear Surendra Gadling bail plea next week after delays

Supreme Court to hear Surendra Gadling bail plea next week after delays

Reader

Trust & legal

Across the network